Ambu stock weighs UBS downgrade against wider GI reach

Published on 10/03/2026 at 23:39 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS

Ambu stock faces a UBS target cut to DKK 72 from DKK 96 on September 15, 2026. Q3 revenue rose 8.8 percent to DKK 1.64 billion.

Architektur-Render eines modernen Medizintechnik-Firmensitzes bei Dämmerung — Ambu A/S (DK0060946788) visualisiert als Architektur-Render einen modernen gläsernen Medizintechnik-Firmensitz bei Abenddämmerung, Illustration mit AI erstellt.

Ambu (DK0060946788) was trading at DKK 67.35 on Nasdaq Copenhagen on October 2, 2026, up DKK 0.25 or 0.37 percent from the prior close of DKK 67.10. The central issue for Ambu stock is whether faster product expansion can offset more cautious earnings expectations.

UBS cuts target to DKK 72

According to Investing.com on September 15, 2026, UBS downgraded Ambu from buy to neutral and lowered its 12-month price target from DKK 96 to DKK 72. The new target lies 6.9 percent above the October 2 price.

The downgrade reflects a narrower growth view. UBS forecasts 10.3 percent annual group sales growth for 2026 through 2030, compared with Ambu's 11 percent to 13 percent target, while its adjusted EBIT margin estimate for 2028 is 15.7 percent.

Q3 revenue reaches DKK 1.64 billion

Simply Wall St reports that Ambu's Q3 2026 revenue reached DKK 1.64 billion for the quarter ended June 30, 2026, up 8.8 percent from DKK 1.51 billion a year earlier. Net income rose 27 percent to DKK 156.0 million, while EPS increased to DKK 0.59 from DKK 0.46.

The earnings mix is important because the revenue increase did not fully settle investor expectations. Simply Wall St says Q3 EPS missed the analyst estimate by 5.2 percent, leaving execution and margin delivery as the next measurable tests for the medical technology group.

GI clearance expands the growth runway

According to Ambu on September 25, 2026, its aScope Gastro and aScope Gastro Large received FDA 510(k) clearance and CE marking for expanded use in flexible sigmoidoscopy. The indication extends the products from upper GI procedures into lower GI care.

Ambu plans commercial launches in the United States and Europe in early 2027, according to the company. That timetable gives the GI platform a defined operating milestone while UBS points to competition in Urology and slower adoption of the aScope 5 Ureteroscope as counterweights.

Price sits below the yearly high

Ambu stock was 39.8 percent below its 52-week high of DKK 111.80 and 19.7 percent above its 52-week low of DKK 56.25 on October 2, 2026. Trading volume was 619,487 shares, and the market capitalization was DKK 17.9 billion.

The next scheduled checkpoint is Ambu's Annual Report 2025/26 on November 5, 2026, followed by the annual general meeting on December 2, 2026, according to Ambu. Until then, the contrast between DKK 1.64 billion in quarterly revenue and the DKK 72 UBS target frames the stock's near-term debate.